N-Glycolyl GM3 ganglioside immunoexpression in oral mucosal melanomas of Chinese

Detection of N-Glycolyl GM3 Ganglioside in Neuroectodermal Tumors by Immunohistochemistry: An Attractive Vaccine Target for Aggressive Pediatric Cancer

(2011) Alejandra M. Scursoni et al.   Clinical & Developmental Immunology

Immunogenicity and safety of a NeuGcGM3 based cancer vaccine: Results from a controlled study in metastatic breast cancer patients.

(2011) Vladimir Mulens et al.   Human vaccines & immunotherapeutics

Heterophilic NeuGcGM3 ganglioside cancer vaccine in advanced melanoma patients: Results of a phase Ib/IIa study

(2010) Marta Osorio et al.   CANCER BIOLOGY & THERAPY

Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer

(2009) Hester van Cruijsen et al.   BMC CANCER

Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy

(2009) Mayrel Labrada et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Detection and Characterization of N-Glycolyated Gangliosides in Wilms Tumor by Immunohistochemistry

(2009) Alejandra M. Scursoni et al.   PEDIATRIC AND DEVELOPMENTAL PATHOLOGY

Differential influence of the tumour-specific non-human sialic acid containing GM3 ganglioside on CD4+CD25- effector and naturally occurring CD4+CD25+ regulatory T cells function

(2008) J. de Leon et al.   INTERNATIONAL IMMUNOLOGY

Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity

(2008) L. Roque-Navarro et al.   MOLECULAR CANCER THERAPEUTICS